Subtopic Deep Dive
Radiomics and Radiogenomics in Lung Cancer
Research Guide
What is Radiomics and Radiogenomics in Lung Cancer?
Radiomics extracts quantitative features from lung cancer medical images to predict tumor genomics and treatment response noninvasively, while radiogenomics correlates these imaging phenotypes with genetic profiles.
Researchers use CT and PET scans to derive radiomic features for machine learning models predicting EGFR mutations and histology in NSCLC. Over 10,000 papers explore these approaches since Aerts et al. (2014) introduced quantitative radiomics (4939 citations). Radiogenomics links imaging traits to genomic data, enabling biopsy-free phenotyping.
Why It Matters
Radiomics predicts EGFR mutation status from CT scans, guiding gefitinib therapy selection as shown in Mok et al. (2009, 8148 citations) where EGFR mutations predicted better outcomes. In NSCLC, radiomic models forecast responses to osimertinib (Soria et al., 2017, 4982 citations) and durvalumab (Antonia et al., 2017, 4344 citations), reducing invasive biopsies. This supports personalized treatment in heterogeneous lung tumors, improving survival via targeted therapies like crizotinib for ALK-positive cases (Solomon et al., 2014, 3159 citations).
Key Research Challenges
Feature reproducibility
Radiomic features vary across scanners and protocols, limiting clinical translation. Aerts et al. (2014) highlighted standardization needs in their quantitative framework. Robust extraction methods remain essential for multi-center validation.
Genomic correlation validation
Linking radiomic signatures to mutations like EGFR requires large cohorts. Travis et al. (2011, 4761 citations) classified adenocarcinoma subtypes, but imaging-genomic ties need prospective trials. Overfitting in ML models complicates reliability.
Integration with treatments
Predicting responses to TKIs like osimertinib (Mok et al., 2016, 3213 citations) demands combined radiomics-clinical models. Heterogeneity in NSCLC staging (Scagliotti et al., 2008, 3191 citations) challenges prognostic accuracy. Real-time clinical deployment lags behind research.
Essential Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · 2009 · New England Journal of Medicine · 8.1K citations
Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the tumor of a mutation o...
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · 2017 · New England Journal of Medicine · 5.0K citations
Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adv...
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Hugo J.W.L. Aerts, Emmanuel Rios Velazquez, Ralph T. H. Leijenaar et al. · 2014 · Nature Communications · 4.9K citations
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi et al. · 2011 · Journal of Thoracic Oncology · 4.8K citations
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · 2017 · New England Journal of Medicine · 4.3K citations
Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZe...
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · 2016 · The Lancet · 3.3K citations
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · 2016 · New England Journal of Medicine · 3.2K citations
Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases) in who...
Reading Guide
Foundational Papers
Start with Aerts et al. (2014, Nature Communications, 4939 citations) for radiomics framework and Mok et al. (2009, 8148 citations) for EGFR context in adenocarcinoma. Add Travis et al. (2011, 4761 citations) for histological classification underpinning radiogenomics.
Recent Advances
Study Soria et al. (2017, 4982 citations) on osimertinib efficacy and Antonia et al. (2017, 4344 citations) on durvalumab, linking to radiomic response prediction advances.
Core Methods
Core techniques: feature extraction (shape, texture from CT), ML classifiers (SVM, random forests), genomic correlation via regression models as in Aerts et al. (2014).
How PapersFlow Helps You Research Radiomics and Radiogenomics in Lung Cancer
Discover & Search
Research Agent uses searchPapers and exaSearch to find radiomics papers on EGFR prediction, then citationGraph on Aerts et al. (2014) reveals 4939-cited works linking imaging to phenotypes. findSimilarPapers expands to radiogenomics in NSCLC from Mok et al. (2009).
Analyze & Verify
Analysis Agent applies readPaperContent to extract radiomic features from Aerts et al. (2014), verifies mutation predictions via verifyResponse (CoVe), and runs PythonAnalysis for statistical tests on reproducibility metrics. GRADE grading scores evidence for clinical translation in lung cancer.
Synthesize & Write
Synthesis Agent detects gaps in radiogenomics validation post-Travis et al. (2011), flags contradictions between targeted therapy papers like Soria et al. (2017). Writing Agent uses latexEditText, latexSyncCitations for NSCLC review papers, and latexCompile for publication-ready manuscripts with exportMermaid for feature extraction diagrams.
Use Cases
"Run statistical analysis on radiomic features predicting EGFR mutations from Aerts et al. dataset."
Research Agent → searchPapers('radiomics EGFR lung') → Analysis Agent → readPaperContent(Aerts 2014) → runPythonAnalysis(pandas correlation matrix, matplotlib ROC curves) → researcher gets validated AUC scores and plots.
"Write LaTeX review on radiogenomics for osimertinib response in NSCLC."
Synthesis Agent → gap detection(osimertinib radiomics) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(Soria 2017, Mok 2016) → latexCompile → researcher gets compiled PDF with figures.
"Find GitHub repos with radiomics code for lung cancer CT analysis."
Research Agent → searchPapers('radiomics lung cancer code') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets inspected repos with PyRadiomics implementations.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'radiomics radiogenomics NSCLC', structures reports with GRADE on Aerts et al. (2014) evidence. DeepScan's 7-step chain verifies radiomic reproducibility with CoVe checkpoints on Mok et al. (2009) mutation data. Theorizer generates hypotheses linking imaging to ALK-targeted therapies from Solomon et al. (2014).
Frequently Asked Questions
What is radiomics in lung cancer?
Radiomics quantifies imaging features from CT/PET to model tumor behavior noninvasively. Aerts et al. (2014) decoded phenotypes using this approach (4939 citations).
What methods link imaging to genomics?
Machine learning correlates radiomic signatures with EGFR/ALK mutations. Integrated models predict responses as in Mok et al. (2009) and Solomon et al. (2014).
What are key papers?
Foundational: Aerts et al. (2014, 4939 citations) on radiomics; Mok et al. (2009, 8148 citations) on EGFR therapy. Recent: Soria et al. (2017, 4982 citations) on osimertinib.
What are open problems?
Standardizing features across sites and validating prospective genomic predictions. Clinical integration with therapies like durvalumab remains unsolved (Antonia et al., 2017).
Research Lung Cancer Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Radiomics and Radiogenomics in Lung Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.